Počet záznamov: 1
SKLB1002, a novel inhibitor of VEGF receptor 2 signaling, induces vascular normalization to improve systemically administered chemotherapy efficacy
SYS 0085161 LBL 00000naa^^22^^^^^^^^450 005 20130304111446.1 100 $a 20130226a2012 m y0sloy0103 ba 101 0-
$a eng $d eng 102 $a SK 200 1-
$a SKLB1002, a novel inhibitor of VEGF receptor 2 signaling, induces vascular normalization to improve systemically administered chemotherapy efficacy $f G. Shen ... [et al.] 215 $c ilustr., grafy, obr. 320 $a Bibliogr. odkazy 320 $a Res. angl. 463 -1
$1 001 sllk_un_cat*0079255 $1 011 $a 0028-2685 $1 200 1 $a Neoplasma $e journal of experimental and clinical oncology $f Cancer Research Institute of the Slovak Academy of Sciences $v Vol. 59, no. 5 (2012), s. 486-493 $1 210 $a Bratislava $c AEPress $d 2012 $1 215 $a s. 475-597 541 1-
$a SKLB1002, nový inhibítor VEGFR 2 receptora signalizácie, indukuje normalizáciu vaskulatúry a cielene zvyšuje účinnosť systémovo podávanej chemoterapie $z slo 606 1-
$3 sllk_un_auth*d009374 $a nádory experimentálne $x farmakoterapia $x patológia $2 mesh 606 2-
$3 sllk_un_auth*d042442 $a faktory rastové endotelové cievne $2 mesh 606 2-
$3 sllk_un_auth*d020533 $a inhibítory angiogenézy $2 mesh 606 1-
$3 sllk_un_auth*d040301 $a receptor 2 pre cievny endotelový rastový faktor $x antagonisty a inhibítory $x použitie terapeutické $2 mesh 606 2-
$3 sllk_un_auth*d009389 $a neovaskularizácia patologická $2 mesh 606 2-
$3 sllk_un_auth*d055806 $a mikrocievy $x účinky liekov $2 mesh 606 1-
$3 sllk_un_auth*d009362 $a metastázy nádorové $x ultraštruktúra $2 mesh 606 2-
$3 sllk_un_auth*d015687 $a hypoxia bunková $x účinky liekov $2 mesh 606 2-
$3 sllk_un_auth*d004317 $a doxorubicín $2 mesh 606 2-
$3 sllk_un_auth*d023421 $a modely zvieracie $2 mesh 610 2-
$a chemoterapia 610 2-
$a vaskulatúra nádoru 701 -1
$3 sllk_un_auth*0028530 $a Shen $b G. $4 070 701 -1
$3 sllk_un_auth*0028531 $a Li $b Y. $4 070 701 -1
$3 sllk_un_auth*0028532 $a Du $b T. $4 070 701 -1
$3 sllk_un_auth*0027671 $a Shi $b G. $4 070 701 -1
$3 sllk_un_auth*0022698 $a Dai $b L. $p State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, the People's Republic of China $4 070 701 -1
$3 sllk_un_auth*0022691 $a Chen $b X. $p State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, the People's Republic of China $4 070 701 -1
$3 sllk_un_auth*0028533 $a Zheng $b R. $4 070 701 -1
$3 sllk_un_auth*0028534 $a Li $b W. $4 070 701 -1
$3 sllk_un_auth*0028535 $a Su $b X. $4 070 701 -1
$3 sllk_un_auth*0022688 $a Zhang $b S. $p State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, the People's Republic of China $4 070 701 -1
$3 sllk_un_auth*0022699 $a Wei $b Y. $p State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, the People's Republic of China $4 070 701 -1
$3 sllk_un_auth*0028536 $a Yang $b S. $4 070 701 -1
$3 sllk_un_auth*0022700 $a Deng $b H. $p State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, the People's Republic of China $4 070 801 -0
$a SK $b BA006 $c 20130226 $g AACR2
Počet záznamov: 1